Key Developments: Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

58.19USD
31 Oct 2014
Price Change (% chg)

$-0.79 (-1.34%)
Prev Close
$58.98
Open
$58.51
Day's High
$58.88
Day's Low
$57.32
Volume
3,272,267
Avg. Vol
1,519,635
52-wk High
$59.03
52-wk Low
$46.32

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb and Lonza expand manufacturing agreement
Thursday, 30 Oct 2014 01:00pm EDT 

Bristol-Myers Squibb Co:Says the company and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement.Says the contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire.Bristol-Myers Squibb and Lonza have been collaborating since 2003 to produce commercial supplies of a biologics medicine marketed by Bristol-Myers Squibb worldwide.Currently, Lonza also produces clinical supplies of an investigational biologics medicine for Bristol-Myers Squibb.  Full Article

Bristol-Myers Squibb Co enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd
Tuesday, 28 Oct 2014 07:00am EDT 

Bristol-Myers Squibb Co:Bristol-Myers Squibb Company and F-star Alpha Ltd. announces that companies, together with F-star Alpha Ltd. shareholders.Enters into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102.FS102 is a novel Phase 1 ready H uman E pidermal growth factor R eceptor 2 (HER2)-targeted therapy in development for the treatment of breast and gastric cancer among a well-defined population of HER2-positive patients who do not respond or become resistant to current therapies.Under terms of agreement, Bristol-Myers Squibb will make payments aggregating to $50 mln that consist of an option fee for the right to acquire F-star Alpha Ltd., payment for certain rights and licenses from F-star Alpha Ltd. and clinical milestne payment upon initiation of the Phase 1 trial.Bristol-Myers Squibb will be responsible for conducting and funding development of FS102 during the option period. Bristol-Myers Squibb can exercise the option to acquire F-star Alpha Ltd. in its sole discretion upon its decision to commence a Phase 2b trial.Total aggregate consideration may reach $475 mln, which includes the payments aggregating to $50 mln, the option exercise fee, and payments upon the commencement of Phase 3 clinical trial and regulatory approvals in the U.S. and Europe.  Full Article

Bristol-Myers Squibb Co reaffirms FY 2014 EPS guidance
Friday, 24 Oct 2014 07:30am EDT 

Bristol-Myers Squibb Co:Says that it is adjusting its FY 2014 GAAP EPS guidance range to $1.15 - $1.25 from $1.50 - $1.60 and confirming its non-GAAP EPS guidance range of $1.70 - $1.80.FY 2014 EPS of $1.78 - Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb, Pharmacyclics and Janssen announce clinical collaboration to evaluate OPDIVO and IMBRUVICA (ibrutinib) in Non-Hodgkin Lymphoma
Monday, 13 Oct 2014 08:00am EDT 

Bristol-Myers Squibb Co, Pharmacyclics Inc and Janssen Research & Development, LLC:Enters into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor in combination with IMBRUVICA.Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Bristol-Myers Squibb has proposed the name OPDIVO which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab.Study will be conducted by Janssen.Additional details of the collaboration were not disclosed.  Full Article

Bristol-Myers Squibb announces collaboration to Evaluate Opdivo in combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer
Monday, 6 Oct 2014 08:00am EDT 

Bristol-Myers Squibb Co:Bristol-Myers Squibb announces collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC).Says establishment of clinical trial collaboration to evaluate safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab).Says with three molecularly targeted oncology therapies ( Zykadia (ceritinib), INC280 and EGF816) from Novartis.Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC).  Full Article

European Medicines Agency validates the marketing authorization application for Bristol-Myers Squibb Co 's Nivolumab in non-small cell lung cancer
Monday, 29 Sep 2014 08:21am EDT 

Bristol-Myers Squibb Co:Says the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) - the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type.Says MAA submitted to the EMA in lung cancer is based on data from the Phase 2 study of nivolumab in third-line pre-treated squamous cell NSCLC (Study -063).Says in addition to the MAA for lung cancer in the E.U., the company previously announced that it has initiated a rolling submission with the FDA for Opdivo in third-line pre-treated squamous cell NSCLC and expects to complete the submission by year-end.  Full Article

Bristol-Myers Squibb Co announces positive phase 3 data for opdivo (Nivolumab) in advanced melanoma patients treated with yervoy
Monday, 29 Sep 2014 03:00am EDT 

Bristol-Myers Squibb Co:Says positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab).Based on a planned interim analysis of the co-primary endpoint, the objective response rate (ORR) was 32 pct (95 pct CI = 24, 41) in the Opdivo arm (n=120) and 11 pct (95 pct CI = 4, 23) in the ICC reference arm (n=47) in patients with at least six months of follow up.Majority (95 pct) of responses were ongoing in the Opdivo arm and the median duration of response was not reached. ORR was based on RECIST criteria as evaluated by an independent radiologic review committee (IRRC).  Full Article

Bristol-Myers Squibb Co announces dividend
Tuesday, 16 Sep 2014 04:30pm EDT 

Bristol-Myers Squibb Co:Declares quarterly dividend of $0.36 per share on the $.10 par value Common Stock of the corporation.The next quarterly dividend will be payable on Nov. 03 to stockholders of record on Oct. 03.The directors also declared a quarterly dividend of $0.50 per share on the $2.00 Convertible Preferred Stock of the corporation.Payable Dec. 01 to stockholders of record on Nov. 07.  Full Article

Bristol-Myers Squibb Co reaffirms FY 2014 EPS guidance - Conference Call
Monday, 8 Sep 2014 02:00pm EDT 

Bristol-Myers Squibb Co:Confirms non-GAAP earnings forecast guidance of $1.70 to $1.80 for FY 2014.  Full Article

Bristol-Myers Squibb Company and Pfizer Inc announces results of secondary analysis of Eliquis Phase 3 AMPLIFY-EXT trial
Sunday, 31 Aug 2014 05:04am EDT 

Bristol-Myers Squibb Company and Pfizer Inc:Announces results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (A pixaban after the initial M anagement of P u L monary embol I sm and deep vein thrombosis with F irst-line therap Y - EXT ended Treatment).The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).Says results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.Says this effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT population.  Full Article

UPDATE 2-Lonza shares drop after revenue forecast cut on weak water business

* Shares fall as much as 8.5 pct (Recasts with fall in shares, adds analyst comments)

Search Stocks